Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Identifying care gaps in Parkinson’s Disease patients eligible for Device-Aided Therapies: Results from using the MANAGE-PD tool in patients from G7 countries
Movement Disorders
Movement Disorders Posters (7:00 AM-5:00 PM)
117
Evaluate care gaps in Parkinson’s disease (PD) patients inadequately controlled on oral medications and eligible for device-aided therapies. 
MANAGE-PD () is a validated tool, developed to support clinical decision-making in timely management of PD-related symptoms. The tool allows grouping  patients into 3 categories: (1) adequately controlled on oral therapy; (2) inadequately controlled on oral therapy but oral optimization possible; (3) inadequately controlled on oral therapy and eligible for device-aided therapies.
Device-aided therapy naïve PD patients currently on oral treatments were identified from the Adelphi Parkinson’s Disease Programme data from G7 countries (US, UK, Germany, France, Italy, Spain, Japan). Patients were categorized based on physician assessment using MANAGE-PD. Unmet needs were based on annual rate for PD-specific falls, dependence in activities of daily living (ADL), PD-specific quality of life (PDQ-39), caregiver burden (ZBI), satisfaction with current treatment, and future treatment discussion with providers. Patients in the categories were compared using ANOVA, t-test, and chi square as appropriate. 
Of the analytical sample (n=2709), 19% were inadequately controlled on oral therapy and eligible for device-aided therapies. Patients classified as category 2 and 3 had incrementally higher unmet needs (higher for category 3 > 2 > 1, p<0.01). In particular, the category 3 patients had the greatest unmet need as demonstrated by: (i) higher number of falls (2.7±4.1, 0.7±2.2), (ii) worse ADL dependence (89.6%, 52.6%), (iii) poorer quality of life (43.2±20.0, 25.5±17.2), (iv) greater caregiver burden (37.1±20.0, 28.1±17.6), and (v) higher dissatisfaction with current treatments (24.2%, 7.7%). However, in this category of patients deemed eligible for device-aided therapies, 50% did not report having any discussion with providers about future device-aided therapies. 
Standardized and validated tools like MANAGE-PD may help in timely identification of patients with significant unmet needs and guide treatment discussions about device-aided therapies.
Authors/Disclosures
Hubert H. Fernandez, MD, FÂ鶹´«Ã½Ó³»­ (Center for Neurological Restoration, Cleveland Clinic)
PRESENTER 		Dr. Fernandez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Fernandez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Fernandez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Intrance. Dr. Fernandez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Fernandez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Fernandez has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Fernandez has received publishing royalties from a publication relating to health care. Dr. Fernandez has received personal compensation in the range of $10,000-$49,999 for serving as a Steering Committee/Advisory Committee Member with Parkinson Study Group.
Per Odin Per Odin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Per Odin has received personal compensation in the range of $0-$499 for serving as a Consultant for Britannia. Per Odin has received personal compensation in the range of $0-$499 for serving as a Consultant for Convatec. Per Odin has received personal compensation in the range of $0-$499 for serving as a Consultant for UCB.
David G. Standaert, MD, PhD, FÂ鶹´«Ã½Ó³»­ (Univ of Alabama - Dept of Neurology) Dr. Standaert has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie, Inc. Dr. Standaert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Curium. Dr. Standaert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. Dr. Standaert has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biohaven. Dr. Standaert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CVS/Pharmacy. Dr. Standaert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for HanAll Biopharma. Dr. Standaert has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Standaert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for F. Hoffman LaRoche. Dr. Standaert has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Aventis. Dr. Standaert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theravance, Inc. Dr. Standaert has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for International Parkinson and Movement Disorder Society. The institution of Dr. Standaert has received research support from Abbvie, Inc. The institution of Dr. Standaert has received research support from American Parkinson Disease Association. The institution of Dr. Standaert has received research support from National Institutes of Health. The institution of Dr. Standaert has received research support from F. Hoffman LaRoche. Dr. Standaert has received publishing royalties from a publication relating to health care. Dr. Standaert has received personal compensation in the range of $500-$4,999 for serving as a Reviewer with National Institutes of Health. Dr. Standaert has a non-compensated relationship as a Chair, Scientific Advisory Board with American Parkinson Disease Association that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Tove Henriksen, MD (Bispebjerg Hospital) Dr. Henriksen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Henriksen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nordic infucare. Dr. Henriksen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Britannia. Dr. Henriksen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck . Dr. Henriksen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for convatec. Dr. Henriksen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AbbVie. Dr. Henriksen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Nordic Infucare. Dr. Henriksen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Britannia.
Joohi Jimenez Shahed, MD, FÂ鶹´«Ã½Ó³»­ (Icahn School of Medicine at Mount Sinai) Dr. Jimenez Shahed has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Dr. Jimenez Shahed has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Medtronic. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Jimenez Shahed has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for BlueRock. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Treefrog. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for RebrAIn. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BlueRock Therapeutics. Dr. Jimenez Shahed has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PhotoPharmics. Dr. Jimenez Shahed has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Emalex. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. The institution of Dr. Jimenez Shahed has received research support from Amneal. The institution of Dr. Jimenez Shahed has received research support from Annovis. The institution of Dr. Jimenez Shahed has received research support from SAGE. The institution of Dr. Jimenez Shahed has received research support from Ono Pharmaceuticals. The institution of Dr. Jimenez Shahed has received research support from BlueRock. The institution of Dr. Jimenez Shahed has received research support from Neuron23. Dr. Jimenez Shahed has received personal compensation in the range of $0-$499 for serving as a Faculty with Movement Disorders Society. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Faculty with Â鶹´«Ã½Ó³»­. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Grant Reviewer with Parkinson Foundation.
Fernando Cubillos Mr. Cubillos has nothing to disclose.
Ali Alobaidi, PharmD (AbbVie Inc) Dr. Alobaidi has received personal compensation for serving as an employee of AbbVie Inc. Dr. Alobaidi has received stock or an ownership interest from AbbVie Inc.
Yash Jalundhwala, PhD (AbbVie Inc) Dr. Jalundhwala has received personal compensation for serving as an employee of AbbVie . An immediate family member of Dr. Jalundhwala has received personal compensation for serving as an employee of AbbVie . Dr. Jalundhwala has received stock or an ownership interest from AbbVie.
Yanjun Bao, PhD (Abbvie Inc) Ms. Bao has received personal compensation for serving as an employee of AbbVie.
Pavnit Kukreja, PharmD (AbbVie) Dr. Kukreja has received personal compensation for serving as an employee of AbbVie. Dr. Kukreja has stock in AbbVie.
No disclosure on file
Jack Wright (Adelphi Real World) Jack Wright has received personal compensation for serving as an employee of Adelphi Real World.
Angelo Antonini, MD Dr. Antonini has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIAL. Dr. Antonini has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ABBVIE. Dr. Antonini has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Antonini has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for THERAVANCE. Dr. Antonini has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. Dr. Antonini has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ABBVIE. Dr. Antonini has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ZAMBON. Dr. Antonini has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BOEHRINGER.